Caldesmon (CALD1) (NM_033157) Human Tagged ORF Clone Lentiviral Particle

SKU RC223989L3V

Lenti ORF particles, CALD1 (Myc-DDK tagged) - Human caldesmon 1 (CALD1), transcript variant 3, 200ul, >10^7 TU/mL

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: Myc-DDK
• Target Symbol: Caldesmon
• Synonyms: CDM; H-CAD; HCAD; L-CAD; LCAD; NAG22
• Vector: pLenti-C-Myc-DDK-P2A-Puro
• Mammalian Cell Selection: Puromycin
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC223989).
• ACCN: NM_033157
• ORF Size: 1692 bp
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
• Shipping: Dry Ice

Reference Data

• RefSeq: NM_033157.2, NP_149347.1
• RefSeq Size: 4546 bp
• RefSeq ORF: 1692 bp
• Locus ID: 800
• UniProt ID: Q05682
• Cytogenetics: 7q33
• Domains: Caldesmon
• Protein Pathways: Vascular smooth muscle contraction
• MW: 65.4 kDa
• Summary: This gene encodes a calmodulin- and actin-binding protein that plays an essential role in the regulation of smooth muscle and nonmuscle contraction. The conserved domain of this protein possesses the binding activities to Ca(2+)-calmodulin, actin, tropomyosin, myosin, and phospholipids. This protein is a potent inhibitor of the actin-tropomyosin activated myosin MgATPase, and serves as a mediating factor for Ca(2+)-dependent inhibition of smooth muscle contraction. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]